Evolent Health, Inc.
EVH
$27.10
-$0.31-1.13%
| Weiss Ratings | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.96 | |||
| Price History | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.71% | |||
| 30-Day Total Return | -17.44% | |||
| 60-Day Total Return | -5.98% | |||
| 90-Day Total Return | -8.87% | |||
| Year to Date Total Return | -16.92% | |||
| 1-Year Total Return | -21.49% | |||
| 2-Year Total Return | 0.99% | |||
| 3-Year Total Return | 30.49% | |||
| 5-Year Total Return | 102.27% | |||
| 52-Week High % Change | -22.83% | |||
| 52-Week Low % Change | 21.39% | |||
| Price | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $36.70 | |||
| 52-Week Low Price | $23.33 | |||
| 52-Week Low Price (Date) | Oct 27, 2023 | |||
| 52-Week High Price (Date) | May 01, 2023 | |||
| Valuation | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.36B | |||
| Enterprise Value | 3.99B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.28 | |||
| Earnings Per Share Growth | 527.13% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.71 | |||
| Price/Book (Q) | 3.15 | |||
| Enterprise Value/Revenue (TTM) | 1.96 | |||
| Price | $27.65 | |||
| Enterprise Value/EBITDA (TTM) | 30.48 | |||
| Enterprise Value/EBIT | 129.46 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 113.59M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -16.63% | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 571 389 6000 | |||
| Address | 1812 N. Moore Street Arlington, VA 22209 | |||
| Website | www.evolent.com | |||
| Country | United States | |||
| Year Founded | 2011 | |||
| Profitability | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 1.51% | |||
| Profit Margin | -5.75% | |||
| Management Effectiveness | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 0.83% | |||
| Return on Equity | -- | |||
| Income Statement | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.96B | |||
| Total Revenue (TTM) | 1.96B | |||
| Revenue Per Share | $17.29 | |||
| Gross Profit (TTM) | 460.47M | |||
| EBITDA (TTM) | 126.50M | |||
| EBIT (TTM) | 29.78M | |||
| Net Income (TTM) | -113.04M | |||
| Net Income Avl. to Common (TTM) | -131.83M | |||
| Total Revenue Growth (Q YOY) | 45.40% | |||
| Earnings Growth (Q YOY) | -194.40% | |||
| EPS Diluted (TTM) | -1.28 | |||
| EPS Diluted Growth (Q YOY) | -222.56% | |||
| Balance Sheet | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 192.83M | |||
| Cash Per Share (Q) | $1.70 | |||
| Total Current Assets (Q) | 683.67M | |||
| Total Preferred Equity (Q) | 178.43 | |||
| Total Equity (Q) | 1.25B | |||
| Current Ratio (Q) | 1.014 | |||
| Book Value Per Share (Q) | $9.38 | |||
| Total Assets (Q) | 2.68B | |||
| Total Current Liabilities (Q) | 674.24M | |||
| Total Debt (Q) | 644.80M | |||
| Total Liabilities (Q) | 1.43B | |||
| Total Common Equity (Q) | 1.07B | |||
| Cash Flow | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -415.54M | |||
| Cash from Financing (TTM) | 281.34M | |||
| Net Change in Cash (TTM) | 8.30M | |||
| Levered Free Cash Flow (TTM) | 171.85M | |||
| Cash from Operations (TTM) | 142.58M | |||
